培美曲塞联合顺铂治疗经蒽环类和紫杉类一线治疗失败的晚期转移性乳腺癌的疗效观察  

Efficacy of pemetrexed combined with cisplatin in the treatment of advanced metastatic breast cancer patients failed to the first-line therapy with anthracyline and taxane

作　　者：李雨遥[1] 田美娟[1] 王丽娜[1] 程婷婷[1] 罗长琴[1] 周小娟[1] 杨谨[1] 

机构地区：[1]西安交通大学医学院第一附属医院肿瘤内科,陕西西安710061

出　　处：《现代肿瘤医学》2013年第4期773-776,共4页Journal of Modern Oncology

摘　　要：目的:观察培美曲塞联合顺铂治疗蒽环类及紫杉类一线治疗失败的晚期转移性乳腺癌的疗效及不良反应。方法:20例晚期转移性乳腺癌患者接受培美曲塞联合顺铂化疗方案。培美曲塞600mg/m2,d1,静脉滴注;顺铂75mg/m2,d1,静脉滴注,21d为1周期。每2个疗程评价疗效,计算疾病进展时间(TTP)和总生存期(OS)。结果:20例患者均可评价疗效,其中CR 0例,PR 6例,SD 8例,PD 6例。中位随访时间为12个月(4-16个月),中位疾病进展时间为4个月(3-14个月),1年生存率50%。主要不良反应为疲乏、胃肠道反应、白细胞减少和口腔黏膜炎。结论:培美曲塞联合顺铂方案治疗蒽环类和紫杉类治疗失败的转移性乳腺癌有较好的疗效,患者耐受性好,值得临床进一步研究。Objective：To observe the efficacy and side effect of pemetrexed combined with cisplatin in the treatment of the advanced metastatic breast cancer （MBC）patitents who have failed to the first -line therapy with anthracycline and taxane. Methods：All 20 patients with advanced MBC patients received pemetrexed and cisplatin,pemetrexed 600mg/m^2, dI , intravenous drip, and cisplatin 75mg/m2, dI , intravenous drip, 21 days as one cycle. Clinical efficacy and adverse reactions were assessed every 2 cycles. The time to progression and overall survival were calculated. Results： All 20 patients were evaluable, CR 0, PR 6, SD 8, PD 6. With a median follow - up of 12 months （4 - 16 months） ,the median time to disease progression was 4 months （3 - 14 months）. 1 -year survival rate was 50%. The most common adverse reactions were fatigue, digestive tract reactions, leukopenia and oral mucositis. Conclusion： Combination of pemetrexed and cisplatin has promising efficacy and an acceptable safety.

关 键 词：培美曲塞 顺铂 晚期转移性乳腺癌(MBC) 

分 类 号：R737.9[医药卫生—肿瘤]